BG105064A - Пептидни антиангиогенни лекарствени средства - Google Patents

Пептидни антиангиогенни лекарствени средства

Info

Publication number
BG105064A
BG105064A BG105064A BG10506400A BG105064A BG 105064 A BG105064 A BG 105064A BG 105064 A BG105064 A BG 105064A BG 10506400 A BG10506400 A BG 10506400A BG 105064 A BG105064 A BG 105064A
Authority
BG
Bulgaria
Prior art keywords
peptide
antiangiogenic drugs
peptide antiangiogenic
drugs
acyl
Prior art date
Application number
BG105064A
Other languages
English (en)
Other versions
BG65065B1 (bg
Inventor
Jack Henkin
Fortuna Haviv
Michael Bradley
Douglas Kalvin
Andrew Schneider
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG105064A publication Critical patent/BG105064A/bg
Publication of BG65065B1 publication Critical patent/BG65065B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до пептиди с формула А0-А1-А2-А3-А4-А5-А6-А7-А8-А9-А10,в която А0 е избран от водород или ацилова група, А10 е хидроксилна група или аминокиселинен амид, и А0, А1, А2, А3, А4,А5, А6, А7, А8 и А9 са аминоацилови остатъци, посочени в описанието.
BG105064A 1998-05-22 2000-12-18 Пептидни антиангиогенни лекарствени средства BG65065B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8374598A 1998-05-22 1998-05-22
US25057499A 1999-02-16 1999-02-16
US27746699A 1999-03-26 1999-03-26

Publications (2)

Publication Number Publication Date
BG105064A true BG105064A (bg) 2001-08-31
BG65065B1 BG65065B1 (bg) 2007-01-31

Family

ID=27374598

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105064A BG65065B1 (bg) 1998-05-22 2000-12-18 Пептидни антиангиогенни лекарствени средства

Country Status (26)

Country Link
EP (1) EP1078002B1 (bg)
JP (3) JP3753612B2 (bg)
KR (1) KR100447696B1 (bg)
CN (1) CN1311796A (bg)
AR (1) AR018371A1 (bg)
AT (1) ATE396204T1 (bg)
AU (1) AU764277B2 (bg)
BG (1) BG65065B1 (bg)
BR (1) BR9910639A (bg)
CA (1) CA2329250C (bg)
CO (1) CO5080726A1 (bg)
CY (1) CY1109118T1 (bg)
CZ (1) CZ299639B6 (bg)
DE (1) DE69938782D1 (bg)
ES (1) ES2307337T3 (bg)
HK (1) HK1037376A1 (bg)
HU (1) HUP0102579A3 (bg)
NO (1) NO326871B1 (bg)
NZ (1) NZ507912A (bg)
PL (1) PL200471B1 (bg)
PT (1) PT1078002E (bg)
SI (1) SI1078002T1 (bg)
SK (1) SK286554B6 (bg)
TR (1) TR200003442T2 (bg)
TW (1) TWI247748B (bg)
WO (1) WO1999061476A1 (bg)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774211B1 (en) 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
US6753310B1 (en) 1998-10-16 2004-06-22 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US20030050246A1 (en) * 2001-07-26 2003-03-13 Fortuna Haviv Peptides having antiangiogenic activity
UY27523A1 (es) * 2001-10-31 2003-05-30 Abbott Lab Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
US7122625B2 (en) 2001-10-31 2006-10-17 Abbott Laboratories Hexa-, hepta-, and octapeptides having antiangiogenic activity
US20030125259A1 (en) 2001-10-31 2003-07-03 Fortuna Haviv Octa- and nonapeptides having antiangiogenic activity
US20030119746A1 (en) * 2001-10-31 2003-06-26 Fortuna Haviv Hepta-and octapeptides having antiangiogenic activity
NZ532367A (en) * 2001-10-31 2006-01-27 Abbott Lab HEPTA-, OCTA- and nonapeptides having antiangiogenic activity
US7037897B2 (en) 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
US7067490B2 (en) 2001-10-31 2006-06-27 Abbott Laboratories Hepta-, Octa-and nonapeptides having antiangiogenic activity
US20030125260A1 (en) * 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity
US7169888B2 (en) 2001-10-31 2007-01-30 Abbott Laboratories Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US7001984B2 (en) 2001-10-31 2006-02-21 Abbott Laboratories Di-, tri-, and tetra-peptides having antiangiogenic activity
KR20040106291A (ko) 2002-03-22 2004-12-17 지피씨 바이오테크 아게 면역억제 화합물, 이의 제조 방법 및 용도
US20030228365A1 (en) * 2002-06-07 2003-12-11 Fortuna Haviv Pharmaceutical formulation
US7432245B2 (en) 2002-06-07 2008-10-07 Abbott Laboratories Inc. Pharmaceutical formulation comprising a peptide angiogenesis inhibitor
EP1853294A4 (en) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2007255910A (ja) * 2006-03-20 2007-10-04 Hokkaido Univ Ｎｍｒシグナルの帰属方法
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008003013A2 (en) * 2006-06-29 2008-01-03 Abbott Laboratories Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
CN104004057B (zh) * 2013-02-25 2016-08-24 上海市第一人民医院 一类抑制新生血管的小肽及其应用
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
TW202328059A (zh) * 2021-09-01 2023-07-16 日商積水醫療股份有限公司 精胺酸衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
WO1993016716A1 (en) * 1992-02-24 1993-09-02 Northwestern University Method and composition for inhibiting angiogenesis
HU224827B1 (hu) * 1996-05-03 2006-02-28 Abbott Lab Új antiangiogén peptidek, azokat kódoló polinukleotidok, és eljárások angiogenezis gátlására
DK0918795T3 (da) * 1997-03-17 2005-03-14 Abbott Lab Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati

Also Published As

Publication number Publication date
HUP0102579A3 (en) 2002-02-28
JP2006232840A (ja) 2006-09-07
KR100447696B1 (ko) 2004-09-08
KR20010025093A (ko) 2001-03-26
CN1311796A (zh) 2001-09-05
JP2002516342A (ja) 2002-06-04
WO1999061476A1 (en) 1999-12-02
PL344415A1 (en) 2001-11-05
NO326871B1 (no) 2009-03-09
PL200471B1 (pl) 2009-01-30
NZ507912A (en) 2002-10-25
TWI247748B (en) 2006-01-21
BG65065B1 (bg) 2007-01-31
BR9910639A (pt) 2002-01-15
EP1078002B1 (en) 2008-05-21
CZ299639B6 (cs) 2008-10-01
DE69938782D1 (de) 2008-07-03
HUP0102579A2 (hu) 2002-01-28
CZ20004327A3 (cs) 2001-08-15
JP2006001923A (ja) 2006-01-05
HK1037376A1 (en) 2002-02-08
JP3753612B2 (ja) 2006-03-08
CA2329250A1 (en) 1999-12-02
CO5080726A1 (es) 2001-09-25
NO20005890L (no) 2001-01-12
AU4407599A (en) 1999-12-13
TR200003442T2 (tr) 2001-03-21
CA2329250C (en) 2012-03-27
CY1109118T1 (el) 2014-07-02
NO20005890D0 (no) 2000-11-21
ES2307337T3 (es) 2008-11-16
SI1078002T1 (sl) 2008-10-31
ATE396204T1 (de) 2008-06-15
SK17632000A3 (sk) 2001-07-10
PT1078002E (pt) 2008-09-02
JP3795906B2 (ja) 2006-07-12
EP1078002A1 (en) 2001-02-28
AU764277B2 (en) 2003-08-14
SK286554B6 (sk) 2008-12-05
AR018371A1 (es) 2001-11-14

Similar Documents

Publication Publication Date Title
BG105064A (bg) Пептидни антиангиогенни лекарствени средства
TW334418B (en) Stilbene derivatives and pharmaceutical compositions
CA2182158A1 (en) Detergents and cleaners containing iminodisuccinates
NZ298999A (en) 4-benzyl-5-hydroxyoxazole derivatives acylated in position-1 by an amino acid, a dipeptide or an acyl group
EP0765916A3 (en) Hydrosilylation crosslinkable compositions
EP0659715A3 (en) Gas generating compositions.
CA2248110A1 (en) (hydroxyalkyl)urea crosslinking agents
HK1017257A1 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants.
EP0662935A4 (en) GAS GENERATOR.
ZA964830B (en) Amino acid amides of 5-amino-1, 3, 4-thiadizone-2-thiols
HUP0103560A3 (en) Dolastatin 15 derivatives
ZA986358B (en) Dolastatin 15 derivatives.
BR9606309A (pt) Composição geradora de gás não-azida de quatro componentes
HUP9801356A3 (en) Triciclic (2-hydroxy-2-methyl-3,3,3-trifluoropropanoyl)-amino-benzoxepine, -benzothiepine, -benzocycloheptene, -indene derivatives and pharmaceutical compositions containing them
HUP0102671A3 (en) Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
EP0577775A4 (en) ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES.
HK1009747A1 (en) New cryptophycins from synthesis.
IL135723A (en) 1'-Ä4-Ä1-4-Fluorophenyl)-1H-indole-3-ylÜ-1-butylÜ-spiroÄisobenzofuran-1-(3H),4'-piperidineÜhydrohal ogenides and pharmaceutical compositions containing them
CA2026990A1 (en) Anti-hiv agent
EP0921805A4 (en) PEPTIDES DETECTED BY MELANOMA-SPECIFIC A1, A2 AND A3 RESTRICTED CYTOTOXIC LYMPHOCYTES, AND THEIR USE
GB9503066D0 (en) Gas generating composition
HUP9900089A3 (en) Peptide derivatives of dolastatin 15
EP0861817A4 (en) GAS GENERATING COMPOSITION
KR970702796A (ko) 에어백용 가스발생제 및 이것을 사용한 에어백용 가스발생기(airbag gas-generating agent and airbag gas generator using the same)
AU4012795A (en) Alzheimer's peptide